Auris Medical Holding (EARS) to Offer Update on Keyzilen Program
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide an update on the KeyzilenTM development program tomorrow, Tuesday, October 11, 2016. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the program update for KeyzilenTM, which is in Phase 3 development for the treatment of acute inner ear tinnitus.
To participate in this conference call, dial 1-855-217-7942 (USA) or +1-646-254-3376 (International), and enter passcode 2939516. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DBV Technologies (DBVT) Announces Topline data from Two-Year OLFUS-VIPES Study; No SAEs Reported
- Global Blood Therapeutics (GBT) Chief Medical Officer Ramos Retired
- Clayton Williams Energy (CWEI) Enters Agreement to Sell Giddings Area Assets in $400M Deal; Names New COO
Create E-mail Alert Related CategoriesCorporate News, FDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!